Kiora Pharmaceuticals (NASDAQ:KPRX) PT Raised to $10.00 at HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX) had its target price lifted by HC Wainwright from $2.00 to $10.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q2 2024 earnings at ($0.95) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at $1.31 EPS, Q1 2025 earnings at ($0.67) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.66) EPS.

Separately, Maxim Group upgraded shares of Kiora Pharmaceuticals to a strong-buy rating in a research report on Thursday, June 13th.

Kiora Pharmaceuticals Trading Up 0.2 %

KPRX stock opened at $4.70 on Tuesday. Kiora Pharmaceuticals has a 52 week low of $3.60 and a 52 week high of $8.98. The company has a fifty day simple moving average of $5.22 and a two-hundred day simple moving average of $5.30.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings data on Friday, May 10th. The company reported $3.42 EPS for the quarter, missing the consensus estimate of $5.58 by ($2.16). The business had revenue of $16.00 million for the quarter, compared to analyst estimates of $16.00 million. On average, equities analysts predict that Kiora Pharmaceuticals will post 0.97 EPS for the current fiscal year.

Insider Activity

In other news, Director Erin Parsons bought 5,260 shares of Kiora Pharmaceuticals stock in a transaction dated Thursday, June 13th. The shares were acquired at an average price of $4.88 per share, with a total value of $25,668.80. Following the completion of the purchase, the director now owns 5,260 shares in the company, valued at approximately $25,668.80. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have bought 9,791 shares of company stock valued at $48,764. 0.94% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. purchased a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals accounts for about 1.5% of Rosalind Advisors Inc.’s holdings, making the stock its 22nd largest holding. Rosalind Advisors Inc. owned 8.76% of Kiora Pharmaceuticals as of its most recent SEC filing. Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.